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Background: Experimental clinical stem cell therapy has been used for more than a decade to alleviate the adverse
aftermath of acute myocardial infarction (aMI). The post-infarcted myocardial microenvironment is characterized by
cardiomyocyte death, caused by ischemia and inflammation. These conditions may negatively affect administered
stem cells. As postnatal cardiomyocytes have a poor proliferation rate, while induction of proliferation seems even
more rare. Thus stimulation of their proliferation rate is essential after aMI. In metaplastic disease, the pro-
inflammatory cytokine interleukin-6 (IL-6) has been identified as potent mediators of the proliferation rate. We
hypothesized that IL-6 could augment the proliferation rate of (slow-)dividing cardiomyocytes.
Methods: To mimic the behavior of therapeutic cells in the post-infarct cardiac microenvironment, human Adipose
Derived Stromal Cells (ADSC) were cultured under hypoxic (2% O2) and pro-inflammatory conditions (IL-1β) for 24h.
Serum-free conditioned medium from ADSC primed with hypoxia and/or IL-1β was added to rat neonatal
cardiomyocytes and adult cardiomyocytes (HL-1) to assess paracrine-driven changes in cardiomyocyte proliferation
rate and induction of myogenic signaling pathways.
Results: We demonstrate that ADSC enhance the proliferation rate of rat neonatal cardiomyocytes and adult HL-1
cardiomyocytes in a paracrine fashion. ADSC under hypoxia and inflammation in vitro had increased the interleukin-
6 (IL-6) gene and protein expression. Similar to conditioned medium of ADSC, treatment of rat neonatal
cardiomyocytes and HL-1 with recombinant IL-6 alone also stimulated their proliferation rate. This was corroborated
by a strong decrease of cardiomyocyte proliferation after addition of IL-6 neutralizing antibody to conditioned
medium of ADSC. The stimulatory effect of ADSC conditioned media or IL-6 was accomplished through activation
of both Janus Kinase-Signal Transducer and Activator of Transcription (JAK/STAT) and Mitogen-Activated Protein
(MAP) kinases (MAPK) mitogenic signaling pathways.
Conclusion: ADSC are promising therapeutic cells for cardiac stem cell therapy. The inflammatory and hypoxic host
post-MI microenvironment enhances the regenerative potential of ADSC to promote the proliferation rate of
cardiomyocytes. This was achieved in paracrine manner, which warrants the development of ADSC conditioned
medium as an “of-the-shelf” product for treatment of post-myocardial infarction complications.
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Postnatal cardiomyocytes (CM) have a limited proliferation
rate that does not suffice to replenish the CM that are mas-
sively lost after Myocardial Infarction (MI). During human
life span approximately half of the cardiomyocytes are
replaced [1,2]. This indicates that there is a significant level
of physiological proliferation of cardiomyocytes. Thus,
novel therapies that promote the proliferation of CM after
acute Myocardial Infarction (aMI) may alleviate post-
infarct complications such as heart failure.
Over the past decade, mesenchymal stem cells (MSC)
emerged as promising candidates for cardiac therapy.
Stem cells and progenitor cells from sources that vary
from bone marrow to adipose tissue and the heart itself
have shown to be beneficial in animal models of aMI
and in clinical trials [3-5]. The current dogma is that
stem cells act primarily through paracrine intervention
in the damaged cardiac microenvironment i.e. through
secretion of trophic factors [6,7]. The secretion profile
and the fate of administrated cells change upon a host
microenvironment. Current research on preconditioning
BM-MSC with the hypoxic and the inflammatory fac-
tors found in post-MI microenvironment improve the
cardioprotective outcome of the therapeutic cells [8-10].
Thus priming Adipose tissue-derived stem cells (ADSC)
for the treatment of MI with hypoxic and inflammatory
conditions might result in the improvement of cardiac
function.
ADSC belong to the family of MSC and are derived
from the adipose vascular stromal fraction as fibroblastic,
spindle-shaped, plastic adherent cells and co-express sev-
eral mesenchymal markers such as CD105, CD90, CD44,
CD29 or CD73 [11,12]. In vitro, ADSC secrete a plethora
of factors that are cytoprotective, promote angiogenesis
and induce proliferation of various cell types [13-15]. In-
deed, in animal models of myocardial infarction, the
intramyocardial administration of ADSC improved cardiac
remodeling and function [16,17]. Yet, the influence of
administered stem cells on the proliferation rate of
cardiomyocytes is poorly studied.
In damaged tissues, interleukin-6 (IL-6) is both
cytoprotective and anti-apoptotic [18,19]. However, during
the late post-MI healing phase IL-6 is upregulated in the
myocardium. This chronic exposure to IL-6 activates as a
compensatory hypertrophic reaction of the surrounding
cardiac tissue and may contribute to cardiac fibrosis. IL-6
acts as a mitogen on several cell types, e.g. on hepatocytes
during liver regeneration. Furthermore, IL-6 facilitates
healing of damaged skeletal muscle through mitotic stimu-
lation of muscle progenitor cells [20,21]. IL-6 binds to the
IL-6/gp130 receptor complex and activates the associated
Janus Kinase (JAK), which phosphorylates, i.e. activates
STAT3 (signal transduction and activator of transcription)
to p-STAT3. The p-STAT3 translocates to the nucleus andinitiates transcription of its responsive genes. STAT3 acti-
vation can also occur through cross-talk between other
mitogenic signaling pathways, such as the mitogen
activated protein kinase (MAPK) pathway [22]. One of the
trophic factors readily secreted by ADSC is IL-6. There-
fore, we hypothesized that IL-6 secreted by ADSC could
stimulate the rate of cardiomyocyte proliferation through
JAK/STAT and MAPK-dependent pathways.
Materials and methods
ADSC isolation and culture
Human subcutaneous adipose tissue samples were ob-
tained after liposuction surgery, which was donated
upon informed consent of the healthy patients with BMI
below 30 (Bergman Clinics, The Netherlands). Adipose
tissue was stored at 4°C and processed within 24 h post
surgery. Following extensive washing with PBS, the tis-
sue was enzymatically digested with 0.1% Collagenase A,
(Roche Diagnostic, Mannheim, Germany) 1:1 in PBS,
containing 1% bovine serum albumine (BSA; Sigma-
Aldrich, Boston, MA) at 37°C for 1 h. Digested tissue
was washed with PBS, 1% BSA to remove the adipocytes
and lipid content. The cell pellet was resuspended in
PBS, 1% BSA and subjected to Lymphoprep (Axis-Shield
PoC, Oslo, Norway) density gradient centrifugation. The
cells from the interface were collected and washed with
PBS, 1% BSA and resuspended in DMEM (Lonza
Biowhittaker, Verviers, Belgium), 10% FBS (Thermo Sci-
entific, Hemel Hempstead, UK), 100 U/mL penicillin,
100 mg/mL streptomycin (Gibco, Invitrogen, Carlsbad,
CA) and 2 mM L-glutamine (Lonza Biowhittaker,
Verviers, Belgium). Cells were seeded in culture flasks at
4x104/cm2, expanded till Passage 3 and used for
experiments. The use of liposuction material as source
of ADSC was approved by of the local Ethics Committee
of University Medical Centre Groningen, given the fact
that it was considered the use of anonymised waste ma-
terial. Yet, for every one of these anonymous donations
the clients gave their consent after information.
Cardiomyocytes isolation and culture
Rat neonatal cardiac tissues were collected and kept in a
head-over-head rotator at 4°C in trypsin (Gibco,
Invitrogen, Carlsbad, CA) overnight. Afterwards, the
tissues were enzymatically digested with 550 U of
Collagenase A, (Roche Diagnostic, Mannheim, Germany)
and filtered through 70 μm cell straine into the cold FCS
solution (Gibco, Invitrogen, Carlsbad, CA). The cell sus-
pension was resuspended in DMEM (Lonza Biowhittaker,
Verviers, Belgium), 10% FCS (Gibco, Invitrogen, Carlsbad,
CA), 100 U/mL penicillin, 100 mg/mL streptomycin
(Gibco, Invitrogen, Carlsbad, CA) and 2 mM L-glutamine
(Lonza Biowhittaker, Verviers, Belgium). Fibroblasts were
depleted through plastic adhesion, non-adhered cells i.e.
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fibronectin-coated flasks (25 μg/ml , Harbor Bio-products,
Noordwood, MA). Animal experiments, i.e. the use of
neonatal rat heart for the isolation of cardiomyocytes was
approved by the local committee for animal experiments
of the Amsterdam University Medical Centre. Animal
experimentation was approved by the local committee
for care and use of laboratory animals and performed
according to strict governmental and international
guidelines. The investigation conformed to Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
HL-1 murine cardiomyocytes were a kind gift of
Dr. William C. Claycomb (Department of Biochemistry
and Molecular Biology, Louisiana State University Health
Science Center, New Orleans, LA, USA). Cells were main-
tained in fibronectin-coated flasks in Claycomb expansion
medium (Sigma-Aldrich, Boston, MA,) supplemented with
10% FBS (Sigma-Aldrich, Boston, MA), 0.1 mM norepin-
ephrine (Sigma-Aldrich, Boston, MA), 100 U/mL penicil-
lin, 100 mg/mL streptomycin (Gibco, Invitrogen, Grand
Island, NY) and 2mM L-glutamine (Lonza Biowhittaker,
Verviers, Belgium) and kept semi-confluent at all times.
Experimental culture conditions
Prior to co-cultures of ADSC and rat neonatal car-
diomyocytes (rnCM) the cells were labeled with the CFDA
SE (green) and CM-DiI (red) respectively according to the
manufacturer ’s instructions (both Molecular probes,
Invitrogen, Grand Island, NY). Co-cultures of ADSC and
HL-1 cardiomyocytes were done after lentivirus tagging
with resp. lentiviruses encoding eGFP and dTomato.
Briefly, on the day of transduction, cells were plated at
1× 106 cells/well in serum-free growth medium containing
5 μg/ml polybrene (Sigma-Aldrich, Boston, MA).
Following overnight incubation, medium was replaced
with normal growth medium containing 10% FBS. The
medium of HL-1 cells was changed once per 24h while
ADSC medium was replenished three times a week. At
five days post-transduction, cells were FACS sorted based
on expression of eGFP or dTOMATO to obtain pure cell
population. To determine the influence of the ADSC
density on cardiomyocyte proliferation, ADSC were
treated with 10 μg/ml mitomycin-C (Sigma-Aldrich,
Boston, MA) for 3h, followed by extensive washing with
PBS prior the co-culture with rnCM and HL-1 cells. The
ADSC cell ratios plated in co-culture conditions varied
from 1:1 to 1:3 for rnCM, while keeping the rnCM at
20,000 cells/cm2. The ADSC ratios in co-cultures with
HL-1 cells varied from 1:1 to 1:4, while keeping the HL-1
cells at 6,000 cells/cm2. Simultaneously, cells were labeled
with 1 μM BrdUrd-bromodeoxyuridine (Sigma-Aldrich,
Boston, MA) for 6h at the end of the experiment. In orderto study the effect of the post-MI microenvironment on
cardiomyocytes, rnCM and HL-1 cells and ADSC were
cultured at ambient oxygen tension 21% O2 (normoxia) or
at 2% O2, (hypoxia). At these oxygen tensions inflamma-
tion was mimicked by continuous treatment with TNF-α
or IL-1β (both 10 ng/ml Peprotech, Rocky Hill, NJ) or
none as a control for 24 and 48h respectively. ADSC
conditioned medium was collected after pre-treatment
according to the experimental procedures for 24h. Subse-
quently, followed by medium replacement without the
stimuli and conditioning in 0% FBS Claycomb Medium
for 24h.
Gene transcript analysis
ADSC were seeded in 12 well plates at 10,000 cells/cm2
in DMEM and treated according to the experimental
procedures. HL-1 cardiomyocytes were seeded in 12 well
plates at 10,000 cells/cm2 in 5% FBS Claycomb medium,
afterwards cells were incubated with 10% FBS (control)
and 0% FBS Claycomb medium or 0% FBS ADSC
conditioned medium for 24h and treated according to
the experimental procedures. Cells were harvested at the
pre-determined time points and RNA was extracted
using the Rneasy Mini Kit (Qiagen Inc., Valencia, CA)
for ADSC and Trizol Reagent (Life technologies,
Carlsbad, CA) method for HL-1 cells according to
manufacturer ’s protocol. Afterwards, 1 μg of total RNA
was reverse transcribed using the First Strand cDNA
synthesis kit (Fermentas UAB, Vilnius, Lithuania)
according to manufacturer ’s instructions. The cDNA
equivalent of 5 ng RNA was used for amplification in
384-well microtiter plates in a TaqMAN ABI7900HT
cycler (Applied Biosystem, Foster City, CA) in a final re-
action volume of 10 μl containing 5 μl SyberGreen uni-
versal PCR Master Mix (BioRad, Richmond, CA) and 6
μM primer mix (forward and reverse). 6 μM of mouse
Beta-2 microglobulin and human GAPDH primer mix
were used as a reference gene. Cycle threshold (CT)
values for individual reactions were determined using
ABI Prism SDS 2.2 data processing software (App-
lied Biosystem, Foster City, CA). To determine the
differences in expression, the CT values were normalized
to reference gene using the ΔΔCt method, normalizing
for the expression of the reference gene and related to
the control treatment. All cDNA samples were amplified
in duplicate. (Table 1)
ELISA
ADSC conditioned medium was collected and filtered
through 0.2 μm filter to remove any residual debris. To
quantify the IL-6 production by ADSC, collected media
were assessed by enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Minneapolis, MN) according to
manufacturer ’s protocol. Absorbance values for individual
Table 1 Primer sequence for qRT-PCR




Cyclin D1 5’-AGCTGGTGTTTGGAAGTAGG-3’ 5’-AAAAGCCTCCTGTGTGAGAC-3’




Human primer Forward Reverse
IL-6 5’-ACTTGCCTGGTGAAAATCAT-3’ 5’-CAGGAACTGGATCAGGACTT-3’
GAPDH 5’-AGCCACATCGCTCAGACAC-3’ 5’-GCCCAATACGACCAAATCC-3’
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Reader with SoftmaxPro 3.0 data processing software. To
assure statistically relevant data, samples were run in trip-
licate from three independent donors.
Immunoblot analysis
Confluent rnCM or HL-1 cardiomyocyte cultures were
serum-starved overnight. Subsequently, 50 μM Stattic
(STAT3 inhibitor) (Calbiochem, Darmstadt, Germany)
or 10 μM UO126 (MEK-1 inhibitor) (Promega, Madison,
WI) and solvent controls were added to HL-1 cells for
2h. Next, rnCM or HL-1 cultures were treated with
ADSC conditioned medium for 30min. Protein lysates
from serum depleted, confluent cultures of HL- 1 cells
were prepared in RIPA buffer (Thermo Scientific,
Rockford, IL,) supplemented with 1% protease inhibitor
cocktail and 1% phosphatase inhibitors cocktail 2, 3
(Sigma-Aldrich, Boston, MA). Cell lysates (20 μg) were
run on 10% polyacrylamide electrophoresis gel and blot-
ted onto nitrocellulose membrane according to standard
protocol. Blots were blocked in Tris-buffered saline
(TBS) containing 5% BSA (Sigma-Aldrich, Boston, MA)
for 1 h. Subsequently, blots were incubated in TBS-1%
Tween containing 5% BSA with primary antibodies to
human p-STAT3 (Y705), STAT3 (Cell Signaling Tech-
nology, Beverly, MA), p-Erk1/2 (Thr 202/Tyr 204),
Erk1/2 (42/44) (Cell Signaling Technology, Beverly,
MA), diluted 1:1000, overnight. Afterwards, blots were
washed and incubated with alkaline phosphatase-
conjugated antibodies to mouse or rabbit IgG, at the di-
lution 1:2000 for 1 h. NBT/BCIP (Bio-Rad, VA) was used
as a substrate for detection. Densitometric analysis was
performed using Totallab 120 (Nonlinear Dynamic,
Newcastle upon Tyne, England).
Immunofluorescence microscopy and image analysis
rnCM and HL-1 cardiomyocytes were seeded semi-
confluent onto polystyrene 8-chamber slides (ThermoScientific, Hemel Hempstead, UK). Subsequently, cells
were serum-starved in serum-free Claycomb Medium
overnight. Afterwards, samples were stimulated with 10
ng/ml IL-6 (Peprotech, Rocky Hill, NJ), conditioned media
of ADSC and conditioned media of ADSC supplemented
with IL-6 neutralizing antibody (1.2 μg/ml) or Mock IgG
(5.33 μg/ml) as a control (all R&D Systems, Minneapolis,
MN) for 24 h. As a growth control, 10% FBS Claycomb
Medium was used. Simultaneously, cells were labeled with
1 μM BrdUrd (Sigma-Aldrich, Boston, MA) for last 6h.
Next, cells were fixed using 2% paraformaldehyde at room
temperature for 20 min. After extensive washing, cells
were permeabilized with 0.5% Triton X-100 in PBS
(Sigma-Aldrich, MA). Samples were treated with 0.7 M
HCl and 0.05% pepsin at 37°C and post-fixed with
paraformaldehyde (4% in PBS). Subsequently, samples
were incubated with primary antibody sheep polyclonal
biotinylated α-BrdUrd (Abcam, Cambridge, UK) diluted
1:100 in PBS with 10% goat serum (First Link Ltd, UK)
overnight. Samples were washed extensively and incubated
with secondary antibody Streptavidin-FITC for HL-1 cells
and Streptavidin-Cy 3 for rnCM (Dako, Carpinteria, CA)
diluted 1:400 in 3 μM DAPI in PBS with 10% mouse
serum (Sanquin, Amsterdam, The Netherlands) for 30
minutes.
To determinate the working mechanism of car-
diomyocyte proliferation, serum-free cultured HL-1
cardiomyocytes were cultured in the presence of 50 μM
JAK1 inhibitor (AG490) or 50 μM STAT3 inhibitor
(Stattic) (Calbiochem, Darmstadt, Germany), 10 μM RAS
inhibitor (FTS) (Cayman Chemical Co., Ann Arbor, MI)
or 10 μM MEK inhibitor (U0126) (Promega, Madison,
WI) and according controls with DMSO for 2h. After-
wards, cells were extensively washed with PBS and cul-
tured in 5% Claycomb medium or ADSC conditioned
medium in the presence of 1μM BrdUrd for 6 h. Next,
samples were fixed using 2% paraformaldehyde and
proceed with BrdUrd staining as mentioned above.
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with Tissue FAXS analysis to quantify percentage of
BrdUrd positive HL-1 cardiomyocytes. Examination was
performed by immunofluorescent microscopy using a
Leica DMRXA microscope and Leica software (Leica
Microsystems), and further quantification was performed
by TissueFAXS using a Zeiss AxioObserver. Z1 microscope
and TissueQuest cell analysis software (TissueGnostics).Statistics
All the data are presented as a means +/− SEM and were
analysed by GraphPad Prism (version 5, GraphPad Soft-
ware Inc.). Statistical significance was determined usingFigure 1 ADSC promote cardiomyocyte proliferation rate in direct co
were co-cultured with mitomycin-C treated ADSC in a 1:1 and 1:3 ratio or n
proliferation in both ratios (1 F, H). Representative micrographs of BrdUrd f
Proliferation was assessed by immunofluorescent detection of 6h incorpora
equipment. B) CM-DiI (red) labeled rnCM were co-cultured in absence, 1:1
rnCM were detected in 1:1 ratio co-culture with ADSC (p < 0.05 1) G) dTom
absence, 1:1, 1:2, 1:3 or 1:4 excess of eGFP lentivirally-tagged ADSC. Increas
culture with eGFP positive ADSC in all ratios (p < 0.05, 1 I). E) Representative
with eGFP ADSC are shown. Cardiomyocyte density was assessed by immuno
with Tissue Gnostics Tissue FAXS equipment. Graphs represent triplicates (withone-way ANOVA with Bonferroni post hoc analysis.
Values of p < 0.05 were considered statistically significant.Results
ADSC promote the rate of cardiomyocyte proliferation in
direct co-culture
We determined whether ADSC enhance the rate of
cardiomyocyte proliferation in direct co-culture. In a 1:1
ratio, mitomycin-C-treated ADSC enhanced proliferation
rate of rnCM 1.4-fold compared rnCM cultures alone
(p < 0.05, Figure 1A, F). Higher ratios (1:3) of ADSC had
no significant benefit (p < 0.05, Figure 1A, F). At the 1:1
ratio, the rnCM density increased 2.5-fold, yet at 3-fold-culture. A) Rat neonatal cardiomyocytes and C) HL-1 cardiomyocytes
one, for 24h. ADSC enhanced rnCM in 1:1 ratio and HL-1 cells
luorescent staining (A, C) and phase contrast (D) are shown.
ted BrdUrd and quantification with Tissue Gnostics Tissue FAXS
and 1:3 ratio of CFDA SE (green) labeled ADSC. Increase densities of
ato lentivirally-tagged HL-1 cardiomyocytes were co-cultured in
ed densities of dTomato HL-1 cardiomyocytes were detected after co-
immunofluorescent micrographs of dTomato HL-1 cells in co-culture
fluorescence detection of dTomato positive HL-1 cells and quantification
SEM) data from n = 3 independent experiments from 3 donors.
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(p < 0.05, Figure 1B, G).
As preparations of neonatal cardiomyocytes comprise
are heterogeneous, we also assessed our findings with
rnCM in the murine cardiomyocyte cell line HL-1. The
proliferation rate of HL-1 cardiomyocytes was dramatic-
ally reduced by serum starvation and served to assess
changes in the rate of proliferation by ADSC. HL-1
cardiomyocytes were co-cultured with ADSC in ratios
1:1 to 1:4. ADSC were pre-treated with mitomycin-C to
induce cell cycle arrest. This allowed for the quantifica-
tion of BrdUrd incorporation in actively proliferating
HL-1 cardiomyocytes. ADSC significantly enhanced the
rate of proliferation of HL-1 cardiomyocytes by 45%
and 46% in 1:1 and 1:3 ratios compared to HL-1
cardiomyocyte alone (p < 0.05, Figure 1C, H). To investi-
gate if various ratios of ADSC influence cardiomyocyte
density, lentivirally eGFP-tagged ADSC (green) were
co-cultured with lentivirally dTomato-tagged HL-1
cardiomyocytes (red). The HL-1 cell density doubled inFigure 2 Conditioned medium of ADSC promotes proliferation rate o
of rat neonatal cardiomyocytes (A) and HL-1 murine cardiomyocytes (B) bo
compared to the serum control (10% FBS). This proliferation rate was not s
rnCM and HL-1 cardiomyocytes for 24h with serum-free conditioned media
none, restored the proliferation of HL-1 cardiomyocytes (p < 0.05). The stim
proliferation rate of rnCM and HL-1 cardiomyocytes under hypoxia was sig
was assessed by immunofluorescence detection of 6h incorporated BrdUrd
C) Representative micrographs of immunofluorescence staining for BrdUrd
with serum-free ADSC conditioned medium after stimulation with IL-1β. Pr
Graphs represent triplicates (with SEM) data from n = 3 independent expera 1:1 and 1:2 ratio and further increased in a 1:3 and 1:4
ratio compared to HL-1 cardiomyocytes alone (p < 0.05,
Figure 1B, D). ADSC enhanced HL-1 cardiomyocyte
proliferation rate in all ratios, no significant differences
were found between various ratios of ADSC to HL-1
cardiomyocytes (p < 0.05, Figure 1E, I).
Conditioned medium of ADSC promotes the rate of
proliferation of HL-1 cardiomyocytes
Possibly, secreted factors of ADSC could cause the
enhanced proliferation rate of cardiomyocytes. The puta-
tive beneficial influence of conditioned media from ADSC
was assessed on rnCM and HL-1 cardiomyocytes subjected
to hypoxia (2% oxygen) and inflammation (TNF- α or
IL-1β) (Figure 2A, B). In serum-containing media, approxi-
mately 10% and 12% of the rnCM proliferated respectively
under normoxia and hypoxia. Serum starvation reduced
the rate of proliferating rnCM to approximately 8%
irrespectively of additional inflammatory factors (TNF-α
or IL-1β) (p < 0.05, Figure 2A). Normoxic conditionedf cardiomyocytes. Serum-free culturing reduced the proliferation rate
th under normoxic (21% oxygen) and hypoxic (2% oxygen) conditions
ignificantly influenced by treatment with TNF-α or IL-1β. Incubation of
of human ADSC (n = 3 donors) pre-stimulated with TNF-α, IL-1β or
ulatory capacity of hypoxically preconditioned ADSC medium on the
nificantly larger than under normoxic conditions (p < 0.05). Proliferation
and quantification with Tissue Gnostics Tissue FAXS equipment.
of HL-1 cardiomyocytes in normal serum (10% FBS), serum-free or
oliferation, i.e. BrdUrd incorporation – green, nuclei (DAPI) – blue.
iments from 3 donors.
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proliferation in high serum. Yet, after serum starvation the
proliferation rate of rnCM increased 1.4-fold after treat-
ment with normoxic conditioned medium of ADSC
(p < 0.05, Figure 2A). The pre-conditioning of ADSC
with TNF-α or IL-1β for the formation of the primed
conditioned medium of ADSC resulted in respectively
1.2-fold increase in the proliferation rate of rnCM
compared to TNF-α or IL-1β primed rnCM under
hypoxia (p < 0.05, Figure 2A). To confirm the positive
effect of the conditioned medium of ADSC on the
enhancement of the cardiomyocyte proliferation rate,
we performed the readout on the pure cardiomyo-
cytes HL-1 cells.
In normal culture medium, approximately 85% of the
HL-1 cardiomyocytes proliferated under both normoxic
and hypoxic conditions. Serum starvation reduced the
fraction of proliferating HL-1 cardiomyocytes almost
two fold under normoxia or hypoxia. Treatment
of serum-free HL-1 cardiomyocytes with TNF-α or
IL-1β did not alter proliferation, irrespective of oxy-
gen concentration. Serum-free-conditioned medium
from normoxically cultured ADSC increased the
proliferation rate of serum-free HL-1 cardiomyocytes
by 18% compared to serum-free HL-1 cardiomyocytes
control (p < 0.05). The proliferation rate of HL-1
cardiomyocytes under normoxic conditions was even
further stimulated (35%, p < 0.05) upon incubation
with conditioned medium from ADSC prestimulated
with TNF-α or IL-1β compared to TNF-α or IL-1β
stimulated serum-free HL-1 cardiomyocytes controls.
The pro-inflammatory stimulation of ADSC with
TNF-α or IL-1β to obtain primed ADSC conditioned
medium ameliorated the cardiomyocyte proliferation
rate as well. Furthermore, IL-1β primed conditioned
medium of ADSC significantly increased (12%, p < 0.05)
the HL-1 proliferation rate compared to nonstimulated
conditioned medium of ADSC. Moreover, conditioned
medium from hypoxia cultured ADSC ameliorated the
proliferation rate of cardiomyocytes even further in
comparison to conditioned medium of normoxia cul-
tured ADSC (31% vs. 18% increase, p < 0.05). In addi-
tion, conditioned medium of hypoxia cultured ADSC
in the presence of pre-stimulation with TNF-α or
IL-1β showed only marginally improvement resulting
in 40% increase in HL-1 cardiomyocyte proliferation
rate (p < 0.05).Hypoxia and pro-inflammatory mediators upregulate IL-6
secretion by ADSC
Treatment of ADSC with IL-1β for 24 h or 48 h induced
respectively 53-fold and 31-fold upregulation of IL-6
gene expression level (p < 0.05, Figure 3A).Under hypoxia, treatment of ADSC with IL-1β for 24
h and 48 h resulted in higher increase of IL-6 gene ex-
pression, respectively by 95-fold and 45-fold ( p < 0.05,
Figure 3B).
The level of secreted IL-6 showed a similar pattern as
the gene expression after stimulation of ADSC with IL-
1β (Figure 3C, D). Stimulation of ADSC with IL-1β ,
induced a 500-fold increase in IL-6 protein secretion
within 24 h, which decreased to approximately 200-fold
at 48 h both under normoxia and hypoxia (p < 0.05,
Figure 3C, D).
IL-6 secreted by ADSC enhances the cardiomyocyte
proliferation rate
Stimulation with IL-6, increased the number of pro-
liferating rnCM from 8% (serum free controls) to 9%
(p < 0.05, Figure 3E). Addition of IL-6 neutralizing anti-
body to the IL-6 treated rnCM reduced the number of
proliferating cells to 7% compared to IL-6 treated controls
(p < 0.05, Figure 3E). Stimulation of rnCM with the serum
free ADSC conditioned medium resulted in increase of
proliferating rnCM to 8.5% compared to serum free
controls. Addition of IL-6 neutralizing antibody to the
conditioned medium of ADSC resulted in significant de-
crease of proliferating rnCM to 7.4% (p < 0.05, Figure 3E).
Adult HL-1 cardiomyocytes were cultured in the pres-
ence of 10% serum. Under serum-free conditions, IL-6
and the conditioned medium of ADSC induced a 24%
and 27% upregulation of the proliferation rate of HL-1
cardiomyocytes respectively, compared to HL-1 serum-
free control (p < 0.05, Figure 3F). Addition of IL-6
neutralizing antibodies to the IL-6 treated HL-1
cardiomyocytes reduced their proliferation rate by 42%
(p < 0.05, Figure 3E) compared to IL-6 treated controls.
Treatment of serum-free conditioned medium of ADSC
with IL-6 neutralizing antibodies also reduced the rate
of HL-1 cardiomyocyte proliferation rate by 13%
compared to conditioned medium of ADSC (p < 0.05,
Figure 3F).
Conditioned medium of ADSC increase cell cycle
progression gene expression profile in HL-1
cardiomyocytes
Cell cycle progression requires activation of cyclin
complexes and G1/S phase transition and associates with
increased expression of c-Myc, while anti-apoptotic
genes such as Bclx are upregulated. Adult HL-1
cardiomyocytes were cultured in the presence of 10%
serum. Serum-free HL-1 cardiomyocytes were cultured
under normoxia and hypoxia in the presence of IL-6 or
IL-1β primed conditioned medium of ADSC. Stimula-
tion of HL-1 cardiomyocytes with the conditioned
medium of ADSC from normoxia and IL-1β primed
resulted in increased gene expression of cyclin D1 and
Figure 3 Hypoxia and pro-inflammatory mediators upregulate IL-6 secretion by ADSC. A, B) Quantitative RT-PCR analysis of gene transcript
levels of IL-6 normalized to GAPDH expression. Gene transcript levels of IL-6 were strongly induced by stimulation with pro-inflammatory
mediators (IL-1β) both under normoxia and hypoxia conditions within 24h and 48h (p < 0.05). The increase of IL-6 gene transcript level was far
stronger after IL-1β stimulation (p < 0.05). C, D). Secreted IL-6, quantified by ELISA, was significantly increased after pre-stimulation of ADSC with
the pro-inflammatory cytokine IL-1β (p < 0.05). Graphs represent triplicates (with SEM) data from n = 3 independent experiments from 3 donors.
E, F) IL-6 is a positive regulator of cardiomyocyte proliferation. In serum-free medium, treatment with IL-6 restored the proliferation of rnCM and
HL-1 murine cardiomyocytes compared to serum-free and serum (10% FBS) controls (p < 0.05). Similarly, pretreatment of human ADSC with IL-1β,
yielded conditioned media that increase proliferation of rnCM and fully restored the proliferation of HL-1 cardiomyocytes in the absence of
serum (p < 0.05). Addition of IL-6 neutralizing antibody to the IL-6 or conditioned medium of ADSC treated serum-free rnCM and HL-1
cardiomyocytes resulted in a significant decreased proliferation of rnCM and HL-1 cardiomyocyte (p < 0.05). Graphs represent triplicates
(with SEM) data from n = 3 independent experiments, normalized to ADSC cultures before the treatment (0h).
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http://www.translational-medicine.com/content/11/1/39cyclin D2 compared to serum-free HL-1 cells, yet not
significant (p < 0.05, Figure 4A). Hypoxia and IL-1β
primed conditioned medium from ADSC resulted in sig-
nificant increase in the gene expression of cyclin D1 and
cyclin D2 by respectively 1.2-fold and 1.3-fold increase
compared to serum-free HL-1 cells (p < 0.05, Figure 4B).
Stimulation of HL-1 cardiomyocytes with IL-6 both
under normoxia and hypoxia did not significantly
affected the gene expression of cyclin D1 and cyclin D2
(p < 0.05, Figure 4A, B). The elevated gene expression of
cyclin D1 and cyclin D2, followed the significant in-
crease of c-myc gene expression in HL-1 cells. Stimula-
tion of HL-1 cells with conditioned medium of ADSC or
IL-1β primed ADSC conditioned medium under
normoxia resulted in significant increase of c-myc gene
expression, respectively by 1.7-fold and 2.2-fold induc-
tion compared to control HL-1 cells (p < 0.05, Figure 4A).
Stimulation of HL-1 cardiomyocytes with hypoxia and
hypoxia with IL-1β primed conditioned medium from
ADSC resulted in significant increase in gene expression
of c-myc, respectively by 1.2-fold and 1.6-fold induction
compared to control HL-1 cells (p < 0.05). Addition of
IL-6 to HL-1 cells resulted in significant increase of c-
myc gene expression only under normoxia by 1.3-foldFigure 4 Conditioned medium of ADSC augments the cell cycle prog
Quantitative RT-PCR analysis of gene transcript levels of cyclin D1, cyclin D2
transcript level of cyclin D1 and cyclin D2 did not change in HL-1 cardiom
normoxia (p < 0.05). B) Gene expression of cyclin D2 showed a significant i
ADSC under hypoxia (p < 0.05). A) Gene transcript levels of c-Myc were sig
medium of ADSC and IL-1β primed ADSC conditioned medium under norm
HL-1 cells showed significant upregulation upon stimulation with condition
(p < 0.05). A, B) Gene transcript levels of apoptotic marker Bclx remained u
conditioned medium of ADSC (p < 0.05). Graphs represent triplicates (with
serum-free HL-1 cardiomyocytes.compared to control HL-1 cells (p < 0.05, Figure 4A).
IL-6 stimulation of HL-1 cells under hypoxia did not
show significant change in HL-1 gene expression of
c-myc compare to serum-free HL-1 cells (p < 0.05,
Figure 4B). Stimulation of HL-1 cardiomyocytes with
ADSC conditioned medium or IL-6 did not change
expression of the antiapoptotic gene Bclx in HL-1
cardiomyocytes either under normoxia or hypoxia
compared to control HL-1 cells (p < 0.05, Figure 4A, B).
Conditioned medium of ADSC increases autocrine IL-6
gene expression in HL-1 cardiomyocytes
HL-1 cardiomyocytes were cultured in the absence of
serum as a control. Stimulation of HL- cardiomyocytes
with IL-6 under serum-free conditions did not effect the
gene expression profile of IL-6, IL-6 receptor α (gp80)
or IL-6 receptor β (gp130) both under normoxia and
hypoxia compared to a serum-free control (p < 0.05,
Figure 5A, B). Addition of ADSC conditioned medium
to HL-1 cells significantly increased gene expression of
IL-6 by 4-fold under normoxia and 5.4-fold under hyp-
oxia compared to a serum-free control (p < 0.05,
Figure 5A, B). Correspondingly, stimulation of HL-1
cardiomyocytes with conditioned medium of ADSCression gene expression profile of HL-1 cardiomyocytes.
and c-Myc normalized to Beta-2 microglobulin expression. A) Gene
yocytes upon stimulation with IL-6 or ADSC conditioned medium in
ncrease upon stimulation with IL-1β primed conditioned medium of
nificantly upregulated upon stimulation with IL-6 or conditioned
oxia (p < 0.05). B) Under hypoxia gene transcript levels of c-myc in
ed medium of ADSC and IL-1β primed conditioned medium of ADSC
nchanged in HL-1 cardiomyocytes upon stimulation with IL-6 or
SEM) data from n = 3 independent experiments, normalized to
Figure 5 Conditioned medium of ADSC increases autocrine IL-6 signaling gene expression in HL-1 cardiomyocytes. Quantitative RT-PCR
analysis of gene transcript levels of IL-6 and IL-6 receptor complex gp130/gp80 normalized to Beta-2 microglobulin expression. A, B) Stimulation
of HL-1 cardiomyocytes with conditioned medium of ADSC and IL-1β primed ADSC conditioned medium resulted in a significant upregulation in
gene expression of IL-6 and the IL-6 receptor components gp130 and gp80 (p < 0.05). Gene transcript level of IL-6 or gp130/gp80 did not change
in HL-1 cardiomyocytes upon stimulation with IL-6 alone (p < 0.05). Graphs represent triplicates (with SEM) data from n = 3 independent
experiments, normalized to serum-free HL-1 cardiomyocytes.
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IL-6 receptor α (gp80) and β (gp130) by respectively 1.6
and 3.3-fold under normoxia compared to a serum-free
control (p < 0.05, Figure 5A) and 1.3 and 2.2-fold under
hypoxia compared to a serum-free control (p < 0.05,
Figure 5B). Addition of IL-1β primed ADSC conditioned
medium to HL-1 cardiomyocytes resulted in higher in-
crease of IL-6 gene expression, resulting in 7-fold in-
crease under normoxia and hypoxia compared to a
serum-free control (p < 0.05, Figure 5A, B). Stimulation
of HL-1 cardiomyocytes with IL-1β primed conditioned
medium of ADSC resulted in significant increase in gene
expression of IL-6 receptor α (gp80) and β (gp130) by
respectively 3.5 and 3.9-fold under normoxia compared
to a serum-free control (p < 0.05, Figure 5A) and 2.6 and
2.2-fold under hypoxia compared to a serum-free con-
trol (p < 0.05, Figure 5B).
ADSC conditioned medium-dependent signaling
pathways targeting the increased rate of cardiomyocyte
proliferation
The phosphorylation of STAT3 in rnCM did not depend
on the presence of serum (Figure 6A, B). Yet, serum free
conditioned medium of ADSC resulted in activated
STAT3 by 4-fold both under normoxia and hypoxiaconditions in serum starved rnCM (p < 0.05, Figure 6A,
B). The peak of activation of p-STAT3 was reached in
rnCM by stimulation with conditioned medium of
ADSC primed with IL-1β both under normoxia and hyp-
oxia resulting in respectively 8.5- and 10-fold increase
compared to the serum free controls (p < 0.05, Figure 6A,
B). In rnCM Erk1/2 was strongly phosphorylated in the
presence of serum (p < 0.05, Figure 6A, C). Under serum
free condition the phosphorylation of Erk1/2 was 2-fold
decreased compared to serum control (p < 0.05, Figure
6A, C). The stimulation of rnCM with the serum free
conditioned medium of ADSC and the IL-1β primed
conditioned medium of ADSC resulted in the strong ac-
tivation of Erk1/2, reaching 1.5-fold increase in compare
to serum free controls (p < 0.05, Figure 6A, C) both
under normoxia and hypoxia. The activation of Erk1/2
in rnCM by the serum free conditioned medium of
ADSC was comparable to the level of phosphorylation
in the rnCM stimulated with serum (Figure 6A, C). In
HL-1 cardiomyocytes, STAT3 and Erk1/2 were both
phosphorylated in the presence of serum. After 24h of
serum deprivation, the phosphorylation i.e. activation, of
these transcription factors was only slightly reduced
(Figure 6D-L). The phosphorylation of STAT3 was
decreased by 3-fold in the presence of the p-STAT3
Figure 6 (See legend on next page.)
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Figure 6 ADSC conditioned medium-dependent signaling pathways targeting increase of HL-1 cardiomyocyte proliferation.
Representative examples of western blot analyses of phosphorylated STAT3 and phosphorylated Erk1/2 in A, B, C) rnCM stimulated with the
conditioned medium of ADSC and IL-1β primed ADSC from normoxic and under hypoxic cultures. The stimulation of rnCM with the serum free
conditioned medium of ADSC resulted in activation of STAT3 and Erk1/2. D, E, F) in HL-1 cardiomyocytes in the presence of STAT3
phosphorylation inhibitor (Stattic) G, H, I) MEK inhibitor (U0126) and J, K, L) both inhibitors (Stattic + U0126). Inhibition of STAT3 phosphorylation
resulted in increased of Erk1/2 phosphorylation. Non-phosphorylated STAT3 and Erk1/2 levels did not change and indicate equivalent protein
controls in all samples (n = 3).
Figure 7 ADSC-dependent signaling pathways targeting HL-1
cardiomyocyte proliferation. A) Treatment of serum-free cultured
HL-1 cardiomyocytes with FBS or B) serum-free conditioned
medium of IL-1β stimulated ADSC resulted in enhanced proliferation
of HL-1 cardiomyocytes (p < 0.05). A, B) Addition of inhibitors of
upstream and downstream of MAPK (RAS and MEK) or JAK/STAT
(JAK1 and pSTAT3) inhibitors all resulted in a significant decrease of
proliferation of HL-1 cardiomyocytes (p < 0.05). Graphs represent
triplicates (with SEM) data from n = 3 independent experiments.
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http://www.translational-medicine.com/content/11/1/39inhibitor (Stattic) (p < 0.05, Figure 6D, E), while Erk1/2
phosphorylation was reduced by 8- and 4-fold with the
MEK inhibitor (U0126) respectively in compare to the
serum and serum-free controls (p < 0.05, Figure 6G, I).
Remarkably, stimulation of HL-1 cardiomyocytes
with serum-free IL-1β-stimulated-ADSC-conditioned
medium resulted in a 2-fold increase in phosphorylation
of STAT3 and Erk1/2, that reached higher level than
serum controls (p < 0.05, Figure 6D-L). Blocking of
STAT3 phosphorylation resulted in reduced levels of
phosphorylated STAT3 and 2-fold increased phosphoryl-
ation of Erk1/2 (Figure 6D, F). In contrast, activation of
phosphorylated STAT3 did not depend on activation of
Erk1/2 phosphorylation (Figure 6D-L). Simultaneous
inhibition of JAK/STAT and MAPK signaling pathway
resulted in reduced levels of phosphorylated STAT3 by
2.7-fold and phosphorylated Erk1/2 by 2-fold (p < 0.05,
Figure 6J-L).
ADSC-dependent signaling pathways targeting HL-1
cardiomyocyte proliferation rate
In the presence of mitogenic factors such as serum and
conditioned medium of ADSC, HL-1 cardiomyocytes
showed an increase in proliferation (25% and 24% re-
spectively, p < 0.05, Figure 7A, B). In the presence of
serum addition of inhibitors targeting upstream or
downstream of JAK/STAT (JAK1 and STAT3) and
MAPK (MEK1) signaling pathway resulted in a
decreased proliferation rate of HL-1 cardiomyocytes
ranging from 31 to 41% (p < 0.05, Figure 7A). Pre-
treatment of HL-1 cardiomyocytes with these inhibi-
tors also reduced the mitogenic effect of conditioned
medium of ADSC, observed as a significant decrease
in the fraction of BrdUrd positive cells by 24 to 37%
(p < 0.05, Figure 7B).
Discussion
In this study we show that Adipose Derived Stromal
Cells (ADSC) enhance the proliferation rate of both pri-
mary CM and a CM cell line, in a paracrine manner and
in direct co-culture in vitro. One of the main stimulators
secreted by ADSC was IL-6. The in vitro hypoxic and
pro-inflammatory preconditioning of ADSC i.e. mimick-
ing the post-myocardial infarction microenvironment
(ischemia and inflammation), strongly upregulated theIL-6 production by ADSC and further augmented
the stimulation of the proliferation of cardiomyocytes.
The IL-6 stimulated cardiomyocyte proliferation was
accomplished through activation of both Janus Kinase-
Signal Transducer and Activator of Transcription (JAK/
STAT) and Mitogen-Activated Protein (MAP) kinases
(MAPK) mitogenic signaling pathways.
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cardiomyocytes with conditioned medium of ADSC
increased their proliferation rate. To mimic the behavior
of therapeutic cells in the post-infarct cardiac micro-
environment, we stimulated ADSC with hypoxia and
pro-inflammatory mediators, which increased their pro-
duction of IL-6. Remarkably, Efimenko and co-workers,
showed that stimulation of MSC from bone marrow
or adipose tissue with high concentrations of TNF-α
did not alter their profile of pro-angiogenic mediators,
which paradoxes to our finding that pro-inflammatory
stimulation augmented regenerative potential of thera-
peutic cells [14]. The differences may be, that different
stimuli (TNF versus IL-1) were used and different rea-
douts, i.e. angiogenesis versus cardiomyocyte prolifera-
tion. Furthermore, our data indicate that hypoxia alone,
but in particular together with a pro-inflammatory sti-
mulus, augment CM proliferation by ADSC condi-
tioned media too. This indicates that hypoxia can furtherFigure 8 Schematic representation of proposed Adipose Stromal Cell
and growth factors, which enhance the proliferation of cardiomyocytes thr
canonical signaling i.e. Erk1/2 activation. The balance between STAT3 and E
activation, through an unknown intermediate. In the absence of STAT3 sign
of stimulatory effect on the proliferation on cardiomyocytes.augment the regenerative potential of ADSC. In con-
trast to current data, not only hypoxia may exert a
beneficial effect on ADSC [15,23]. We found that in-
flammation had far stronger effect on the ADSC se-
cretion profile. Although hypoxia itself did not alter
IL-6 gene expression levels by ADSC, in combination
with inflammatory mediators enhanced regenerative po-
tential of ADSC.
Stimulation of rnCM and adult HL-1 cardiomyocytes
with IL-6 resulted in an enhanced level of the
cardiomyocyte proliferation rate. Targeting IL-6 with neu-
tralizing antibodies against IL-6 in the presence of IL-6 or
conditioned medium of ADSC resulted in decreased rate
of cardiomyocyte proliferation. The blocking of IL-6 in
ADSC conditioned medium only partially inhibited
positive effect of ADSC conditioned medium on
cardiomyocyte proliferation rate. This suggests that either
conditioned medium of ADSC contains additional only
mitogenic factors or that other factors promote rnCM and-derived IL-6 signaling pathway. The ADSC-secreted cytokine IL-6
ough canonical signaling i.e. STAT3 activation and through non-
rk1/2 signaling is governed by STAT3, which can suppress Erk1/2
aling, IL-6-RAS-activated Erk1/2 can compensate for the potential loss
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IL-6.
This is corroborated by our observation that stimula-
tion of HL-1 cardiomyocytes with conditioned medium
of ADSC resulted in a significant increase of c-myc and
IL-6 receptor complex gp130/gp80, while stimulation
with IL-6 alone did not show significance gene
expressions changes.
IL-6 signaling involves activation of downstream sig-
naling of two major signaling pathways i.e. JAK/STAT
and MAPK-Erk1/2 that are mitogenic in various cell
types. Thus, we analyzed the significance of both of
these pathways on cardiomyocyte proliferation rate. Our
study identifies a previously uncharacterized function of
conditioned medium of ADSC signaling in regulating
cardiomyocyte proliferation. Stimulation of rnCM and
HL-1 cardiomyocytes with conditioned medium of
hypoxically and proinflammatory primed ADSC resulted
in strong phosphorylation of STAT3 and Erk1/2, the
downstream targets of JAK/STAT and MAPK activation
(Figure 8).
Similarly, previous studies on skeletal muscle have
shown that regular exercise causes damage that is
followed by increased IL-6 level. The released IL-6
activates the JAK/STAT signaling pathway and augments
repair of skeletal muscle [24]. Recent clinical therapies
with postconditioning of the ischemic heart show benefi-
cial effect on the reduction of the scar size due to the ac-
tivation of STAT3 [25] and involvement of IL-6 in this
process [26]. In addition, pro-inflammatory cytokines
such as TNF-α related TWEAK or ligands from EGF
family such as neuregulin and HB-EGF provided evi-
dence for engagement MAPK in induction of the car-
diomyocyte proliferation rate [27-29].
Conditioned medium of ADSC activated the down-
stream JAK1 and JAK2/TYK2 that lead to their target
STAT3 Tyr705 phosphorylation in rnCM and HL-1
cardiomyocytes. Blocking of JAK1 with commonly used
JAK/STAT inhibitor did not diminished the level of
phosphorylated STAT3, suggesting that JAK/STAT acti-
vation can also occur through JAK2/TYK2 [30]. Remark-
ably, direct inhibition of phosphorylated STAT3 with
Stattic resulted in reduced STAT3 and increased levels
of phosphorylated Erk1/2 (Figure 6). This suggests that
the stimulated proliferation rate of HL-1 cardiomyocytes
is a balance between STAT3 signaling and MAPkinase
signaling [31]. Although prolonged inhibition of one of
the upstream or downstream of JAK/STAT or MAPK
pathways lead to decreased proliferation rate of HL-1
cardiomyocytes either in the presence of mitogenic
factors or conditioned medium of ADSC.
The therapeutic benefit of stem cells for cardiac ther-
apy is well-accepted, however the stem cell response to
the host ’s post-MI microenvironment is uncertain [32].The main mode of action of cardiac stem cell therapy is
through paracrine mechanisms. Indeed, the intravenous
administration of conditioned culture media from bone
marrow derived MSC in pigs improved cardiac remodel-
ing and perfusion [33,34]. To unravel the mechanism of
paracrine therapeutic benefit of cardiac stem cell ther-
apy, we subjected cardiomyocytes to the conditioned
medium of ADSC.
Conclusions
The post-infarct cardiac microenvironment consists of an
imbalanced level of inflammatory and anti-inflammatory
mediators that correlate with the outcome of diseased
myocardium. Cytokines might exert different function in
time and dose dependent manner. Prolonged chronic high
levels of IL-6 after MI are considered as a cause of hyper-
trophy and heart failure. Recent studies demonstrate that
pro-inflammatory cytokines can activate cardioprotective
signaling pathways in the post-infarct heart. IL-6 though
might exert dynamic actions and act as a potent
“myokine”, where in a rapid response to acute myocardial
infarction it activates cardioprotective pathways [35],
resulting in increase in cardiomyocyte proliferation. Appli-
cation of the conditioned medium derived from thera-
peutic cells rather than cells themselves would circumvent
the problem of retention in cardiac stem cell therapy.
Additionally, the current approach of use of primed
conditioned medium of therapeutic stem cells offer “off -
the-shelf” product, which may be used for multiple
injections.
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